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Abstract
Background—Patients with primary focal segmental glomerulosclerosis (FSGS) resistant to
current treatment regimens are at high risk of progression to end stage kidney disease. Antifibrotic
agents, such as tumor necrosis factor α (TNF-α) antagonists, are a promising strategy to slow or halt
the decline in renal function, based on preclinical and clinical data.
Study Design—Phase I clinical trial to assess the pharmacokinetics, tolerability, and safety of
adalimumab, a human monoclonal antibody to TNF-α.
Setting and Participants—Ten patients (4 male and 6 female), age 16.8±9.0 yr, and estimated
GFR 105±50 mL/min/1.73 m2, were studied as out-patients
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Intervention—Adalimumab, 24 mg/m2 every 14 days for 16 weeks (total 9 doses)
Outcomes—Pharmacokinetic assessment, tolerability, and safety
Measurements—Estimated glomerular filtration rate, proteinuria, and pharmacokinetic
assessment after initial dosing and steady state
Results—Pharmacokinetic evaluation indicated that the area under the curve was decreased by 54%
(P<0.001) and clearance was increased by 160% (P<0.01) in patients with resistant FSGS compared
to healthy controls and patients with rheumatoid arthritis. Adalimumab was well tolerated with no
serious adverse events or infectious complications attributable to the drug. Proteinuria declined by
≥50% in 4 of 10 treated patients.
Limitations—Insufficient power to assess safety or efficacy of adalimumab therapy for patients
with resistant FSGS
Conclusions—Pharmacokinetic assessment demonstrated increased clearance of adalimumab in
patients with resistant primary FSGS and validated the need for evaluating the disposition of novel
therapies in this disease to define appropriate dosing regimens. The study provides a rationale to
evaluate efficacy of adalimumab as an antifibrotic agent for resistant FSGS in Phase II/III clinical
trials.
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INTRODUCTION
Adalimumab is a human monoclonal antibody to tumor necrosis factor α (TNF-α). It is
approved by the US Food and Drug Administration (FDA) for use as an anti-inflammatory
agent to treat adults with rheumatoid arthritis, ankylosing spondylitis, Crohn disease, or
psoriasis and children with juvenile idiopathic arthritis (1,2,3). However, despite increasing
use of this agent, there is little information about the effect of anti-TNF-α agents in renal
disorders (4,5).
Experimental and clinical data support the role of TNF-α in the pathogenesis of a wide spectrum
of kidney diseases including FSGS. In Buffalo/Mna rats that spontaneously develop nephrotic
syndrome and FSGS, there is upregulation of renal expression of TNF-α (350-fold higher than
control levels) before the onset of proteinuria (6).TNF-α levels are elevated in plasma and urine
obtained from patients with FSGS (7,8). Moreover, the ratio of TNF to interleukin 13 (IL-13)
levels in serum, an index of inflammation, remains high in patients who are unresponsive to 4
weeks of corticosteroid treatment and who presumably have FSGS (9). Production of TNF-α
is enhanced in cultured peripheral blood mononuclear cells obtained from children with steroid-
resistant nephrotic syndrome and FSGS (10,11). Expression of the cytokine is also increased
within the renal parenchyma of patients with FSGS and TNF-α immunoreactivity correlates
with the extent of interstitial fibrosis (12). Finally, TNF-α causes endothelial cell injury and
increases glomerular permeability in vitro (13); these two adverse effects are reversed by
extracts of the herbs, Ganoderma lucidum and Tripterygium wilfordii Hook F, respectively
(14,15). Taken together, these findings support a role of TNF-α in mediating proteinuria and
renal fibrosis in FSGS.
There are case reports suggesting the efficacy of anti-TNF-α therapies in patients with nephrotic
syndrome (16,17). In contrast, there is evidence that anti-TNF-α agents can induce glomerular
injury that manifests as membranous nephropathy or immune complex nephritis (18). These
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findings underscore the need to systematically assess the application of anti-TNF-α therapy in
patients with primary FSGS.
Despite the potential benefit of adalimumab therapy in primary and secondary
glomerulopathies, there are no data to guide dosage recommendations for monoclonal
antibodies in these diseases (3). In glomerular disorders, a number of factors could alter
monoclonal antibody pharmacokinetics (pharmacokinetics) and mandate dose adjustment to
achieve safe and therapeutic drug levels. Adalimumab is an IgG protein (molecular weight of
148 kDa) and massive urinary losses could result in lower peak levels and reduced cumulative
exposure to the biological agent. Extracellular fluid volume status can be altered in nephrotic
syndrome resulting in potential changes in the volume of distribution of adalimumab. Finally,
the effect of nephrotic syndrome on bioavailability of subcutaneously injected drugs has not
been systematically studied.
The primary purpose of the first portion of the Novel Therapies for Resistant FSGS (FONT)
study was to evaluate pharmacokinetics characteristics, tolerability, and safety of agents that
hold promise as antifibrotic therapies. The first two agents selected for testing were
rosiglitazone and adalimumab. The findings for rosiglitazone were recently published (19). In
this report, we summarize the Phase I evaluation of adalimumab in patients with resistant
primary FSGS. Secondary objectives were to determine the effect of clinical parameters and
demographic variables on adalimumab pharmacokinetics.
METHODS
Patients
Patients, 2-41 years of age, with primary FSGS and estimated GFR (GFRe) >40 mL/min/1.73
m2 were eligible to participate in the FONT study. Eligibility was confirmed by review of the
kidney biopsy by a central pathologist. Patients were resistant to glucocorticoids prescribed in
accord with current practice guidelines and to one additional therapy such as mycophenolate
mofetil, azathioprine, cyclosporine, or tacrolimus. The protocol was approved by the
Institutional Review Board at each site and patient or parent/ guardian consent (and assent
where appropriate) was obtained prior to enrollment.
Participants were off all immunosuppressive medications except for minimal doses of
glucocorticoids for at least 4 weeks prior to enrollment. Therapy with angiotensin converting
enzyme inhibitors and angiotensin receptor blockers was permitted, provided dosages were
not modified during the study except for safety indications. In the FONT Phase I trial, patients
were assigned to receive rosiglitazone or adalimumab. This report summarizes the results in
the latter group.
The adalimumab (Humira®, Abbott Laboratories Inc., www.abbott.com) dose was 24 mg/
m2 injected subcutaneously every 14 days, maximum 40 mg. Adalimumab was given for 16
weeks and patients were evaluated at Weeks 0, 1, 2, 4, 8, 12, and 16. The following clinical
and laboratory data were measured at each assessment: vital signs, height, weight, severity of
edema, serum creatinine, estimated glomerular filtration rate (eGFR; calculated by using the
Cockroft-Gault equation if ≥ 18 yr and age- and sex-appropriate Schwartz formula for < 18
yr), urine protein-creatinine ratio in a first morning specimen, and serum albumin, fasting total
cholesterol, AST, and ALT concentrations. CH50 and ANA titers were measured at Weeks 0,
8 and 16.
All adverse effects were tabulated and causal relationship to adalimumab was determined by
the site investigator. Patient satisfaction with therapy was assessed at Week 16 using the
Treatment Satisfaction Questionnaire for Medications (TSQM) instrument (20).
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Patients underwent two comprehensive pharmacokinetics assessments -- an initial
pharmacokinetics study with the first dose of adalimumab at Week 0 and a steady state
assessment after patients had received adalimumab for 16 weeks.
Patients were admitted to the General Clinical Research Unit. Patients were fasting at the start
and then fed a standard diet throughout the procedure. After obtaining a baseline blood sample,
patients received their biweekly dose of adalimumab. Additional serum samples were obtained
at 2, 8, 12, 30, and 42 hr. Approximately 15 mL of blood was drawn during each
pharmacokinetics study. Urine was collected from 0-2, 2-12, 12-24, 24-36, and 36-48 hr for
measurement of protein excretion. A validated assay to measure urinary adalimumab levels
was unavailable for this study. Blood samples were immediately centrifuged for 10 min at 4°
C, and serum was stored at −80°C until assayed.
Analytical methods
Serum adalimumab concentrations were quantified by a validated two-antigen sandwich
ELISA (under supervision of Abbott Laboratories). The assay sensitivity limit was 0.25 μg/
mL serum. The interassay accuracy was 101-102% and the precision was equal to 4.7% at
quality control sample concentrations of 6.0-36.1 ng/mL. Serum TNF-α levels were measured
using a commercial ELISA (R&D Systems, www.rndsystems.com).
Pharmacokinetics Analysis
Non-compartmental pharmacokinetics analysis of adalimumab was conducted using
WinNonlin v4.1 (Pharsight, www.pharsight.com) with linear up-log down for AUC
determination. Non-compartmental analysis was justified because previous data demonstrated
stationary pharmacokinetics. The following pharmacokinetics parameters were analyzed: peak
plasma concentration (Cmax), time to peak drug concentration (Tmax), AUC from time 0 to
infinity (AUC0-∞) for single dose, AUC from time 0 to 336 hr (AUC0-336) for steady state
dosing, apparent clearance (Cl/F), apparent volume of distribution (Vz/F), and half-life (T1/2).
In order to eliminate differences secondary to the amount of adalimumab administered, data
for Cmax, Ctr (trough plasma concentration), and AUC0-∞ data were adjusted to a dose of 40
mg. Clearance data were scaled to a weight of 70 kg and then raised to a power of 0.75 to
minimize differences related to body size (21).
Statistical methods
Data are presented as mean±standard deviation (SD). Descriptive analyses for
pharmacokinetics parameters, demographic variables, and laboratory tests include mean,
standard deviation, and median as appropriate. Differences between groups were assessed with
analysis of variance followed by paired comparisons using a t-test with a Bonferroni correction.
Spearman correlations were determined for key clinical characteristics (serum albumin, urine
protein-creatinine ratio, eGFR, age, BSA) versus each pharmacokinetics parameter of interest
(AUC, Cl/F, Vz/F, T1/2, Ctr, Cmax). The correlations and resultant P values from the univariant
assessments were analyzed for inclusion into a multiple regression model for prediction of Cl/
F, Ctr, and Cmax for adalimumab. Data that did not follow a normal distribution were
transformed or ranked prior to model assessments. Model building consisted of multiple
regression analysis with forward selection. The final model was selected based on significance
of each clinical variable as a predictor of the adalimumab pharmacokinetics outcome as well
as the overall R2. P values <0.05 were considered significant and given the exploratory nature
of the study, P values 0.05-0.10 were considered to show a trend
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Figure 1 summarizes the number of patients who were screened and enrolled in the FONT
Phase I trial. Ten patients were assigned to adaliumab with 20% having collapsing, 10%
cellular, 20% tip, and 50% not otherwise specified (NOS) lesions. Nine participants completed
the 16-week treatment period and underwent all of the laboratory evaluations. One patient
exited after 12 weeks because of refractory proteinuria and severe edema, which prompted the
site investigator to restart treatment with tacrolimus. Patients were 16.8±9.0 yr (range: 6-36
yr), 40% were prepubertal, 60% female, 30% nonwhite, and BSA was 2.2±1.0 m2 (Table 1).
Concomitant medications included HMG CoA reductase (3-hydroxy-3-methylglutaryl
coenzyme A) inhibitors (30%), ACE inhibitors/angiotensin receptor blocking drugs (100%),
diuretics (40%), and low-dose prednisone (20%).
The key laboratory results at Weeks 0 and 16 are presented in Table 2. Group level comparisons
in urine protein-creatinine ratio, GFRe, and serum albumin were not significant. In the 9
patients who completed the 16-week Treatment Period, 4 achieved at least a 50% reduction in
proteinuria, with the decline beginning at Week 2 and reaching a nadir at Week 16. In no case
did the urinary protein excretion decline to normal.
No significant changes were noted in body weight, blood pressure, hematocrit, liver function
tests, CH50 level (data not shown), or ANA titer (Table 3). Serum TNF-α levels were unaltered
by the 16 week course of adalimumab therapy (3885±3223, pre-treatment versus 4721±3808
pg/ml, post-treatment, P=0.6).
Pharmacokinetics
Adalimumab pharmacokinetics data were available for all 10 patients at the single and steady-
state evaluations. One patient who withdrew after 12 weeks had the steady state
pharmacokinetics evaluation performed at that time. Because the single dose half-life in the
FONT study was 159 hours, 12 weeks represented steady state conditions and
pharmacokinetics results are presented for the full group of 10 patients. The adalimumab doses
at the initial and final pharmacokinetics evaluation were 33.7±8.8 mg. Concentration versus
time profiles for single dose adalimumab administration are presented in Figure 2.
The adalimumab pharmacokinetics parameters are provided in Table 4. Data from rheumatoid
arthritis patients after a single dose of antibody are provided for comparison (22,23). The
published results for Cl/F and AUC0-∞ for adalimumab were not adjusted to a 70 kg body
weight; however, the average weight in these studies was 69.7 kg. Initial dose and steady state
pharmacokinetics parameters from the FONT patients were similar with the exception of Cl/
F, which was higher at steady state versus initial dosing (P<0.05). Single dose
pharmacokinetics parameters (Tmax, Cmax (dose corrected), T1/2, AUC0-∞, Vz/F, and Cl/F) in
the FSGS group were different than in patients with rheumatoid arthritis. Steady-state
parameters from FONT patients could not be compared to the rheumatoid arthritis cohort
because these data were not obtained in the latter population. Tmax was reduced almost 3-fold
(55±62 vs 130±55 hr, P<0.02) in the FONT patients, suggesting faster absorption from the
injection site. However, Cmax was also lower in FSGS patients compared to those with
rheumatoid arthritis, 9.2±4.1 versus 13.7±2.7 μg/mL, respectively, P<0.02.
The steady state half-life (T½ss) demonstrated an inverse linear relationship with the urine
protein-creatinine ratio and direct correlation with the serum albumin concentration. The
T½ss was shorter in FSGS patients who exhibited higher urine protein-creatinine ratio ratios
and lower serum albumin levels (Figures 3a and 3b). The ranked T½ss versus urine protein-
creatinine ratio showed a correlation coefficient, r value −0.899 (95% CI −0.9761 to −0.6207),
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r 2=0.8082 (P<0.001). Linear correlation analysis between ranked T½ss and serum albumin
indicated that the r value was 0.7586, (95% CI 0.2467 to 0.9395), r2=0.5755 (P=0.01). A similar
but less significant relationship was noted when half life versus urine protein-creatinine ratio
or serum albumin was assessed after the first dose. Weaker relationships were found when the
AUCss and Cl/Fss were plotted against urine protein-creatinine ratio. There were 3 outliers to
these relationships: 2 patients who had significantly lower AUCss and higher Cl/Fss versus
urine protein-creatinine ratio correlations than the best fit line and 1 patient who had an
extremely high urine protein-creatinine ratio (29 mg/mg) and moderate AUCss and Cl/Fss
values. Reanalysis of AUCss and Cl/Fss versus urine protein-creatinine ratio linear correlational
analysis without these 3 patients demonstrated highly significant relationships (P<0.002 and
P<0.02, respectively) (Figures 4a and 4b). A significant negative relationship between Vz/F
and urine protein-creatinine ratio at steady state was demonstrated; r −0.9193 (95% CI −0.9948
to −0.1955), r2 0.8451.
Multiple regression analyses were employed to assess the contribution of all variables from
the univariate analyses to the prediction of steady state pharmacokinetics responses (Cl/Fss,
Ctrss, AUCss, Cmaxss). T½ was not included because it represents a hybrid variable of Vz/F and
Cl/F. Two relationships of similar magnitude were determined for Cl/Fss with race constant
in both models and albumin or urine protein-creatinine ratio reflecting the second variable in
the respective models. Race was coded as “1” if white and “2” if nonwhite.
Equation 1
Equation 2
Modeling of equations for the prediction of Ctr and Cmax was also evaluated because the
predicted Ctr at 80% Emax would be 4-8 μg/mL based on a biweekly 40 mg dose utilized in
rheumatoid arthritis patients (24). Only 3 FONT patients achieved a Ctr between 4-8 μg/mL.
Patients with “therapeutic” Ctr concentrations had changes in GFRe (+29.3± 71.1 mL/min/
1.73 m2), urine protein-creatinine ratio (−10.4 ± 8.00), and serum albumin (+1.03±1.10 g/dL)
that represented clinical improvements. In contrast, the 7 patients who did not achieve Ctr ≥4
μg/mL had worsening and/or less favorable clinical laboratory outcomes, based on GFRe
(−10.9±24.5 mL/min/1.73m2), urine protein-creatinine ratio (−0.79±5.83), and serum albumin
(−0.29±0.49 g/dL). The serum albumin concentration and urine protein-creatinine ratio
independently predicted Ctrss in the FSGS patients.
Equation 3
Equation 4
No linear relationships or multivariable models were found that predicted Cmax values.
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Patient tolerance of adalimumab was assessed by the TSQM questionnaire, which provides
data in four domains (maximal score of 100 in each category, higher scores indicate better
tolerance). The scores were: effectiveness 61±21, side effects 92±18, convenience 71±20, and
global satisfaction 59±26. The results were similar to those previously reported with
rosiglitazone (19), except for slightly lower scores for convenience and global satisfaction.
This probably reflects the need for injections to administer the adalimumab.
Safety
Adverse events were generally mild (Table 5). There was a total of 9 events, with only 1 deemed
to be “probably related” to adalimumab therapy. This event, an injection site reaction, was
mild. Two severe adverse events were noted (edema, bilateral avascular necrosis) but they were
not attributed to adalimumab and the Ctr was <4 μg/mL. Three events were recorded as fever,
cough, and/or body aches and were not considered drug-related. Only 1 of these 3 patients
achieved Ctr concentration, 10 μg/mL, which was outside the therapeutic range of 4-8 μg/mL.
None of the patients required discontinuation of adalimumab because of adverse events.
DISCUSSION
This is the second report of the FONT study group and complements our description of the
pharmacokinetics, tolerability, and safety of rosiglitazone in patients with resistant FSGS
(19). The findings are consistent with studies demonstrating the potential benefit of inhibition
of TNF-α with etanercept (25) or pentoxifylline (26) in small cohorts of patients with idiopathic
membranous nephropathy. The current results with adalimumab are the first to document
different pharmacokinetics of a human monoclonal antibody in patients with primary FSGS
and nephrotic syndrome. Importantly, pharmacokinetics parameters (Tmax, Cmax, T½, AUC, V/
F, and Cl/F) differed in FSGS patients compared to a reference population of rheumatoid
arthritis patients (22,23). Specifically, the FSGS population attained lower Cmax, AUC, V/F,
shorter Tmax and T1/2, and higher Cl/F values after a single-dose compared to rheumatoid
arthritis patients, reflecting diminished exposure to adalimumab.
Significant relationships between urine protein-creatinine ratio or serum albumin and half life
of adalimumab were predicted by univariate correlational analyses. Although the statistical
strength of the relationships with ranked albumin and proteinuria varied depending on the
pharmacokinetics parameter, measurement of protein excretion may be more practical because
it can be applied to individual patients. No relationship between half life and GFRe was
appreciated. This suggests a novel approach to dosing antibodies in nephrotic patients based
on a marker of disease severity, i.e., urine protein-creatinine ratio. This would be analogous to
dosing drugs that are eliminated by the kidney via glomerular filtration by calculating the
creatinine clearance. In nephrotic syndrome, excessive amounts of large molecular weight
molecules such as albumin are lost in the urine or the interstitial space. Urinary losses of
adalimumab were not measured in this study because a validated assay was unavailable.
However, renal IgG clearance (0.055 mL/min/1.73 m2) has been reported to be one-third the
albumin clearance (0.16 mL/min/1.73m2) in 15 patients with FSGS and normal GFR (27). This
represented a loss of 2216 mg/m2/day and 199 mg/m2/day of endogenous albumin and IgG,
respectively. Serum protein concentrations were reduced in those with renal losses of albumin
and IgG (27).
We explored the relationship of urine protein-creatinine ratio to other pharmacokinetics
variables in the FSGS patients. Since Cl/F is a primary pharmacokinetics variable and can
significantly alter drug exposure (AUC), we plotted AUC and Cl/F versus urine protein-
creatinine ratio. Although there was a linear relationship for the majority of our FSGS patients,
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three patients deviated from the relationship. At a urine protein-creatinine ratio of
approximately 5, Cl/F values for 2 of 4 patients were 3-5 fold higher, and hence their data
departed significantly from the line of identity. Additionally, the patient with the highest urine
protein-creatinine ratio value (29 mg/mg), had a severely reduced Cl/F from that predicted
based on the line of identity. An alternative clearance mechanism besides urine protein-
creatinine ratio may be activated in patients with higher than expected adalimumab clearances
that is lacking in patients with severely reduced drug clearance.
The use of clinical factors to predict estimates of pharmacokinetics variables such as Cl/F and
Ctr was examined in order to design appropriate dosing regimens. In addition to albumin and
urine protein-creatinine ratio, race predicted adalimumab Cl/Fss. Patients classified as
“nonWhite” had a 2-fold increase in Cl/F versus patients classified as “White”. Differences in
IgG Cl/F based on race have not previously been reported. Validation studies are needed prior
to drafting guidelines on dosing based on the findings in this study.
There was evidence of clinical improvement, manifested as increases in GFRe and serum
albumin and decreases in urine protein-creatinine ratio in the FSGS patients whose adalimumab
Ctr exceeded 4 μg/mL, the therapeutic target in rheumatoid arthritis (24). Patients with
rheumatoid arthritis show strong dose-response relationships (28). Rheumatoid arthritis
patients who develop anti-adalimumab antibodies demonstrate lower Ctr and reduced response
to therapy. Thus, antibody generation may cause lower than predicted adalimumab
concentrations and lack of response in FSGS patients. Anti-adalimumab antibody levels were
unavailable in the FONT Phase I study cohort. The safety data in our study did not demonstrate
concentration-related side effects in patients with Ctr >4 μg/mL. Despite alterations in
adalimumab pharmacokinetics characteristics in patients with resistant FSGS, the FDA
approved dosage of 24 mg/m2 or 40 mg maximum single dose does not appear to be unsafe in
this patient population.
There were no serious adverse events attributed to adalimumab in this study. In particular, no
patients developed infections or a new malignancy. This is encouraging given that adalimumab
may be associated with serious infections such as reactivation of latent tuberculosis (29) and
malignancies in immunosuppressed patient populations (30), even after fairly limited exposure
times. None of the participants developed an elevated ANA titer, SLE-like syndrome, or de
novo glomerular disease, rare events in adalimumab-treated patients (18,31). Patients were
treated for a relatively short period of time and were not receiving concomitant
immunosuppressive medications, factors that can influence the risk of serious adverse effects
(29,30,31). Adalimumab was not discontinued in any case because of other drug-related serious
or minor adverse events. Despite the general safety and tolerance observed in this Phase I study,
intensive surveillance for infections and malignancies will be mandatory in future Phase II and
III clinical trials. This is underscored by the recent fatality related to disseminated
histoplasmosis that occurred in a patient with rheumatoid arthritis who was enrolled in a gene
therapy protocol and who was receiving anti-TNF-α therapy (32). This will help define the
risk:benefit ratio of this therapy as an antifibrotic agent in patients with resistant primary FSGS
and is germane in light of a recent report documenting successful use of anti-TNF-α treatment
for recurrent FSGS post-kidney transplant and other kidney diseases (33,34).
There are several limitations in this Phase I study. First, we could not measure urinary loses
of adalimumab due to lack of a validated assay. Second, determination of human anti-human
antibody titers were not done and need to incorporated in future Phase II studies. Third, this
Phase I study was designed to assess pharmacokinetics, tolerability, and safety and not efficacy.
It is difficult to extrapolate an estimate of efficacy, based on the heterogeneous response in this
cohort. Finally, the small sample size and relative short duration of treatment were insufficient
to define the full spectrum of potential side effects.
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In conclusion, this Phase I study demonstrated that the clearance of adalimumab is increased
in patients with resistant primary FSGS. Clinical and laboratory characteristics such as race,
proteinuria and serum albumin may enable prediction of drug handling in this population. The
drug was well tolerated and safe in this small cohort with a limited duration of treatment. These
results justify further Phase II testing of adalimumab as an antifibrotic agent to slow the
progression of renal disease.
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CONSORT diagram summarizing patient screening and enrollment in the FONT Phase I trial
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Adalimumab concentration versus time curves after Single Dose. Note that the drug
concentrations are provided as ng/mL to enhance the clarity of the graphs.
Joy et al. Page 13













Figures 3a and 3b.
3a: Linear regression model of ranked T½ versus UP:C (urine protein-creatinine ratio) at steady
state. Data were ranked so that they would follow a normal distribution. The model resulted
in r = −0.8990 (95% Confidence Interval −0.9761 to −0.6207), r2 −0.6207, p<0.001.
3b: Linear regression model of ranked T½ versus ranked serum albumin at steady state. Data
were ranked so that they would follow a normal distribution. The model resulted in r = 0.7586
(95% Confidence Interval 0.2467 to 0.9395), r2 0.5755, p=0.01
Joy et al. Page 14













Figures 4a and 4b.
4a: Linear regression model of Cl/Fss versus UPCR (urine protein-creatinine ratio). The model
resulted in r = 0.8465 (95% Confidence Interval −0.1615 to −0.0693), r2 0.7165, p=0.02.
4b: Linear regression model of lnAUCss versus UP:C (urine protein-creatinine ratio). The
model resulted in r = 0.9446 (95% Confidence Interval 1.3 to 8.095), r2 0.8923, p=0.001
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Table 4
Pharmacokinetic Variables in FSGS compared to Rheumatoid Arthritis
Single Dose Steady State
FSGS RA FSGS
Tmax (hr) 55±62a 130±55& 34.2±9.8
Cmax (μg/mL)# 9.2±4.1a 13.7±2.7 12.8±8.3
T½ (hr) 159±155b 389±71 273±402
AUC (μg hr/mL)# 1649±1202b 3622±587 2019±1693
Cl/F (mL/hr)+ 20.2±8.4b,c 11.2±2.0 53.2±43.3
Vd/z (L) 3.5±1.3b 5.7±0.9 6.6±5.4
Note: Data are provided as mean±SD. FSGS data are from the FONT study, rheumatoid arthritis (RA) values are from a previous study. 21
AUC data at single dose is 0-∞ and at steady state is 0-360 hours (represents a dosing interval)
&
Investigator Brochure cited in ref 21
#
normalized to a 40 mg dose
+
body weight scaled to a power of 0.75 (ref 21)
a
P<0.02 comparing FSGS single dose and RA single dose
b
P<0.001 comparing FSGS single dose and RA single dose
c
P<0.05 comparing FSGS single dose and FSGS steady state
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